Cross Timbers Royalty Trust CRT
13.10 USD +0.24 (+1.87%)
At closeNov 3, 2026, 4:02 PM EST
12.70 -0.40 -3.05%
After hours · Nov 3, 4:02 PM ET
12.82 Day range 13.29
7.34 52-week range 14.63
- YTD
- +64.78%
- 1 year
- +69.47%
- Market cap
- 78.60M
- Revenue (ttm)
- 8.69M
- Profit margin
- 88.67%
- EPS (ttm)
- 0.53
- Shares out
- 6.00M
- P/E ratio
- 24.72
- Dividend
- 1.08 (10.81%)
- Ex-dividend date
- Oct 30, 2024
- YTD return
- +64.78%
- 1-year return
- +69.47%
- Volume
- 24.34K
- Avg volume
- 25.45K
- Open
- 12.88
- Previous close
- 12.86
- Day's range
- 12.82 – 13.29
- 52-week range
- 7.34 – 14.63
- Beta
- 0.54
6M +2.42 (+22.49%)
Key statistics
- Enterprise value
- 59.00M
- PEG ratio
- 0.00
- Price / sales
- 6.61
- Price / book
- 21.51
- Dividend yield
- 10.81%
- Payout ratio
- 100.00%
- Revenue growth
- -50.30%
- Free cash flow
- 0
- Total cash
- 1.18M
- Total debt
- 0
- Return on equity
- 288.74%
- Short % of float
- 0.19%
- 50-day average
- 10.39
- 200-day average
- 11.50
Next earnings
Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | 0.25 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | 0.22 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | 0.25 | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | 0.40 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | 0.41 | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | 0.51 | — | — |
About Cross Timbers Royalty Trust
Cross Timbers Royalty Trust operates as an express trust in the United States. It holds 90% net profits interests in certain producing and nonproducing royalty and overriding royalty interest properties in Texas, Oklahoma, and New Mexico; and 75% net profits working interest in four properties in Texas and three properties in Oklahoma. The company was founded in 1991 and is based in Dallas, Texas.
- Sector
- Energy
- Industry
- Oil & Gas E&P
- Country
- United States
- Website
- crt-crosstimbers.com
News
IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial 
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer 
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium 
CROSS TIMBERS ROYALTY TRUST DECLARES OCTOBER CASH DISTRIBUTION 
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists 
Analyzing Cross Timbers Royalty Trust (NYSE:CRT) and Navigator (NYSE:NVGS) 
Cross Timbers Royalty Trust (CRT) To Go Ex-Dividend on September 30th 
CROSS TIMBERS ROYALTY TRUST DECLARES SEPTEMBER CASH DISTRIBUTION 
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC) 
Innate Pharma Reports First Half 2026 Business Update and Financial Results
Your note
Sign in to keep a note on CRT — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Mraz, Amerine & Associates, Inc. | 0.76% | 45,876 | 439.03K | Sep 29, 2024 |
| UBS Group AG | 0.41% | 24,876 | 238.06K | Sep 29, 2024 |
| NewEdge Advisors, LLC | 0.35% | 20,777 | 198.84K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.29% | 17,119 | 163.83K | Sep 29, 2024 |
| Morgan Stanley | 0.25% | 15,052 | 144.05K | Sep 29, 2024 |
| LPL Financial LLC | 0.24% | 14,366 | 137.48K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Series Portfolios Tr-Unusual Whales Subversive Republican Trading ETF | 0.00% | 69 | 660 | Dec 30, 2023 |